Through 2024, Ozempic has generated DKK 343.8 billion in reported sales for Novo Nordisk.
Readers often search “how much money has novo nordisk made from ozempic?” The cleanest way to answer is to add the company’s own brand sales year by year. Ozempic launched in late 2017 and appears as a separate line in Novo Nordisk’s filings. This page pulls those numbers together, shows the running total, and points you to the sources so you can verify them in a minute.
How Much Money Has Novo Nordisk Made From Ozempic?
Using Novo Nordisk’s published brand sales, Ozempic revenue adds up to DKK 343,759 million from 2018 through 2024. That is revenue, not profit. The figure covers Ozempic only and excludes Wegovy and other semaglutide products. For quick reference, the table below lists each year and the short driver note.
| Year | Ozempic Sales (DKK m) | What Drove It |
|---|---|---|
| 2018 | 1,796 | First full year; early US roll-out. |
| 2019 | 11,237 | Broader launch; rising GLP-1 share. |
| 2020 | 21,211 | Launch in 50+ markets; strong uptake. |
| 2021 | 33,705 | Growth in both US and international markets. |
| 2022 | 59,750 | Rapid demand; periodic supply limits. |
| 2023 | 95,718 | High demand across regions. |
| 2024 | 120,342 | Further scale and capacity additions. |
Two primary sources anchor those numbers. Novo Nordisk’s Annual Report 2024 financials list Ozempic revenue of DKK 120,342 million for 2024 and describe the growth. The company’s year-end statement for 2018 reports DKK 1,796 million in Ozempic sales; see the Q4 2018 financial statement.
Method: What Counts As “Made” From Ozempic
When people ask how much money Novo Nordisk has made from Ozempic, they almost always mean revenue. Revenue is the value of product sold before costs, rebates, and taxes. Profit is what’s left after costs, and brand-level profit isn’t broken out in public filings. That is why the best public yardstick is revenue by brand.
To build the total, we take each year’s Ozempic revenue from the filings and add them together through 2024, which is the most recent full year with audited numbers. That gives a single figure anyone can audit back to the source pages in a few clicks.
How Much Money Novo Nordisk Made From Ozempic — Year By Year
The step-change is clear once you scan the narrative around each year. Ozempic started small, then scaled as weekly GLP-1 treatment became standard in type 2 diabetes. Below, each short section pairs the number with plain-English context so the curve makes sense.
2018: First Full Year On Shelves
Ozempic’s first full year delivered DKK 1,796 million in sales, with the brand sold in a limited set of countries and the US leading the way. That figure sits in the company’s year-end statement linked above.
2019: Crossing The First Big Milestone
Sales jumped to DKK 11,237 million as the launch spread to more markets and prescribers moved to once-weekly treatment. The annual report credits both North America and international regions for the lift.
2020: Momentum Builds
Ozempic reached DKK 21,211 million, with distribution across 50+ countries and strong demand through the year. Market share for GLP-1 treatment in diabetes rose, and access widened in clinics and health plans.
2021: Reach And Adherence Improve
Revenue climbed to DKK 33,705 million. Company commentary points to growth in both the US and abroad as access widened and weekly dosing kept patients on therapy. The brand was available in more than 70 countries by year end.
2022: Demand Outruns Supply At Times
Revenue accelerated to DKK 59,750 million. Novo Nordisk noted periodic supply constraints tied to rapid uptake and capacity limits, while stepping up promotion and market access work in both regions.
2023: A Breakout Year
Sales reached DKK 95,718 million. Demand remained strong in the US and abroad, and awareness of GLP-1 medicines grew fast. The company’s report attributes the lift to both regions.
2024: Scale Hits A New Level
Ozempic delivered DKK 120,342 million in reported sales for the year, backed by expanded capacity and steady demand. That brings the cumulative total through 2024 to DKK 343,759 million.
Reading The Numbers The Right Way
Filings present sales in Danish kroner (DKK). Growth rates often appear “at constant exchange rates” to isolate currency swings; the absolute revenue figures are reported in DKK. When you track money “made” from a product, stick to the brand sales in DKK for each year and avoid mixing in constant-exchange-rate growth. That keeps the math clean.
Revenue Versus Profit
Revenue answers the main question, yet it doesn’t tell you margin. Costs of goods, freight, promotions, rebates, and taxes all sit below the revenue line in the consolidated statements. Brand-level margin data aren’t public, so any profit estimate would be guesswork. This article stays with audited revenue to keep a solid, verifiable answer.
Why The Number Surged
Several forces worked together: weekly dosing that patients prefer, broader guideline adoption in diabetes care, payer coverage in large markets, and more factory capacity. Public updates also show periods where supply ran tight, which can hold back sales even when demand is high. The arc across 2021–2024 reflects both rising demand and the build-out needed to serve it.
What About 2025?
Quarterly updates can swing with pricing, rebates, and supply. That is normal in this market. The full-year series through 2024 remains the best anchor for the total asked in the headline.
Second Look: The Running Total Over Time
To show compounding, the table below adds a running total next to each year. It’s the same revenue series you saw earlier, now with a cumulative column.
| Year | Ozempic Sales (DKK m) | Cumulative (DKK m) |
|---|---|---|
| 2018 | 1,796 | 1,796 |
| 2019 | 11,237 | 13,033 |
| 2020 | 21,211 | 34,244 |
| 2021 | 33,705 | 67,949 |
| 2022 | 59,750 | 127,699 |
| 2023 | 95,718 | 223,417 |
| 2024 | 120,342 | 343,759 |
How To Verify The Figures Yourself
Open the company’s reports and search “Ozempic” in each year. You will see the brand sales printed in the diabetes care section. For 2024, the digital annual report and the PDF list DKK 120,342 million. For 2023, the annual report shows DKK 95,718 million in brand sales. For 2018, the year-end statement lists DKK 1,796 million. Add each year together and you will land on the same total shown here.
Notes On Scope And Terms
Scope: Ozempic sales only. Wegovy, Rybelsus, and older GLP-1 brands are excluded to keep a clean answer to the headline question.
Currency: Figures are reported in DKK as printed in the filings. Exact US dollar conversions vary with exchange rates, so this article leaves the sums in the company’s reporting currency.
Gross-to-Net: US sales include rebates and discounts negotiated with plans and government programs. Those items sit between list price and revenue and can move year to year.
Data Quality: Numbers cited here come from audited annual reports or company announcements. They match the brand-level lines that investors rely on.
Step-By-Step: Recreate The Total In Minutes
Here’s a simple way to pull the same answer from scratch using only public pages and a notepad:
Find Each Year’s Number
Open the 2018 year-end statement and copy the Ozempic figure. Do the same for 2019, 2020, 2021, 2022, 2023, and 2024. Each report uses the same brand name and lists sales in Danish kroner. You can search within the PDF for “Ozempic” to jump straight to the right line.
Add Them Once
Write the seven numbers in one column and add them. Do not mix in Wegovy or the wider GLP-1 category. Do not add constant-exchange-rate growth rates; those are for trend, not sums. That’s all you need here.
Cross-Check With Context
Read the few sentences around each line item. They explain what drove the change that year: new launches, broader access, supply steps, or mix shifts. These short notes help you tell the story behind the curve without guessing.
Common Misreads To Avoid
Mixing Ozempic And Wegovy
They share the same active ingredient, yet they are different brands with different labels and dose ranges. If you mix them, you inflate the answer and drift from the question people type into search.
Using List Prices Instead Of Reported Sales
List price times prescriptions can look tempting, but rebates and discounts make that math unreliable. The brand sales line already bakes in those adjustments, which is why investors track it.
Adding Growth Rates Instead Of Money
Growth rates at constant exchange rates are handy for trend reading. They are not money. If you try to add them, the total goes off by a wide margin.
Projecting Profit From Revenue
Margin varies by market, dose, and channel. The company doesn’t publish brand-level margin, so back-of-the-envelope profit math will be a guess. Stick with revenue when the question is “how much money has novo nordisk made from ozempic?” and point readers to the filings for detail.
Plain-English Takeaway
From a small base in 2018 to DKK 343.8 billion by 2024, Ozempic became a giant franchise for Novo Nordisk. The headline number is revenue, not profit, yet it shows the scale of demand and the company’s push to meet it with more capacity and wider access. Ask one question, get one solid answer you can check.